Genzyme in Belgium

Our sales, marketing and corporate affairs offices in Zaventem

Genzyme established its first offices in Belgium in 1993 to support European expansion of its diagnostics and therapeutics sales activities. In 2000, with the acquisition of BioMatrix, Genzyme Belgium expanded to include a team of sales and marketing professionals for Belgium and Luxembourg. Since 2002, Genzyme Belgium operates from Zaventem, just outside the Brussels region, and comprises all business activities for the Belux region as well as some international and European functions. It also houses Genzyme’s Corporate Affairs department for Europe.

Our manufacturing facilities in Geel

In October 2001, Genzyme Corporation took over the personnel and assets of Pharming N.V. in Geel, Belgium to develop Genzyme’s first biotherapeutics manufacturing facility in Europe.

In a first phase a fed-batch production line was build for the manufacturing of therapeutic monoclonal antibodies. This technology is currently used by Genzyme to produce a therapy for leukemia patients. Regulatory approval for commercial production of this product in Geel is expected in 2009-2010.

In the second phase a perfusion production line was build for the manufacturing of an enzyme replacement therapy for the treatment of Pompe disease. This is the first available treatment for this debilitating and often fatal inherited muscle disorder. Regulatory approval for commercial production of this product in Geel for Europe was received on February 25^th, 2009.

Genzyme’s overall investment in Geel totals €300 million. It currently employs approximately 350 people.

Terms and Conditions of Use | Privacy Policy | © 2010 Genzyme Corporation. All rights reserved.